Molecular and Structural Basis of Pan-Resistance to BTK Inhibitors and Degraders
RNA-seq (gene expression) · human · 100 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Chronic lymphocytic leukemiaThis series is part of our curated briefing on it.
- Samples
- 100 samples: 100 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE330399_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1463785 and SRA study SRP698726. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 100 sample titles: 100 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9725349 TMD8 Cells,Wildtype Clone 1,DMSO Treatment
- GSM9725350 TMD8 Cells,Wildtype Clone 1,Zelbrudomide Treatment
- GSM9725351 TMD8 Cells,Wildtype Clone 1,Bexobrutidig Treatment
- GSM9725352 TMD8 Cells,Wildtype Clone 1,Pomalidomide Treatment
- GSM9725353 TMD8 Cells,Wildtype Clone 1,Venetoclax Treatment
- GSM9725354 TMD8 Cells,Wildtype Clone 1,Zelbrudomide-Venetoclax Treatment
- GSM9725355 TMD8 Cells,Wildtype Clone 1,Bexobrutidig-Venetoclax Treatment
- GSM9725356 TMD8 Cells,Wildtype Clone 1,Pomalidomide-Venetoclax Treatment
- GSM9725357 TMD8 Cells,Wildtype Clone 2,DMSO Treatment
- GSM9725358 TMD8 Cells,Wildtype Clone 2,Zelbrudomide Treatment
- GSM9725359 TMD8 Cells,Wildtype Clone 2,Bexobrutidig Treatment
- GSM9725360 TMD8 Cells,Wildtype Clone 2,Pomalidomide Treatment
- GSM9725361 TMD8 Cells,Wildtype Clone 2,Venetoclax Treatment
- GSM9725362 TMD8 Cells,Wildtype Clone 2,Zelbrudomide-Venetoclax Treatment
- GSM9725363 TMD8 Cells,Wildtype Clone 2,Bexobrutidig-Venetoclax Treatment
- GSM9725364 TMD8 Cells,Wildtype Clone 2,Pomalidomide-Venetoclax Treatment
- GSM9725365 TMD8 Cells,Wildtype Clone 3,DMSO Treatment
- GSM9725366 TMD8 Cells,Wildtype Clone 3,Zelbrudomide Treatment
- GSM9725367 TMD8 Cells,Wildtype Clone 3,Bexobrutidig Treatment
- GSM9725368 TMD8 Cells,Wildtype Clone 3,Pomalidomide Treatment
- GSM9725369 TMD8 Cells,Wildtype Clone 3,Venetoclax Treatment
- GSM9725370 TMD8 Cells,Wildtype Clone 3,Zelbrudomide-Venetoclax Treatment
- GSM9725371 TMD8 Cells,Wildtype Clone 3,Bexobrutidig-Venetoclax Treatment
- GSM9725372 TMD8 Cells,Wildtype Clone 3,Pomalidomide-Venetoclax Treatment
- GSM9725373 TMD8 Cells,Wildtype Clone 4,DMSO Treatment
- GSM9725374 TMD8 Cells,Wildtype Clone 4,Zelbrudomide Treatment
- GSM9725375 TMD8 Cells,Wildtype Clone 4,Bexobrutidig Treatment
- GSM9725376 TMD8 Cells,Wildtype Clone 4,Pomalidomide Treatment
- GSM9725377 TMD8 Cells,Wildtype Clone 4,Venetoclax Treatment
- GSM9725378 TMD8 Cells,Wildtype Clone 4,Zelbrudomide-Venetoclax Treatment
- GSM9725379 TMD8 Cells,Wildtype Clone 4,Bexobrutidig-Venetoclax Treatment
- GSM9725380 TMD8 Cells,Wildtype Clone 4,Pomalidomide-Venetoclax Treatment
- GSM9725381 TMD8 Cells,Wildtype Clone 5,DMSO Treatment
- GSM9725382 TMD8 Cells,Wildtype Clone 5,Zelbrudomide Treatment
- GSM9725383 TMD8 Cells,Wildtype Clone 5,Bexobrutidig Treatment
- GSM9725384 TMD8 Cells,Wildtype Clone 5,Pomalidomide Treatment
- GSM9725385 TMD8 Cells,Wildtype Clone 5,Venetoclax Treatment
- GSM9725386 TMD8 Cells,Wildtype Clone 5,Zelbrudomide-Venetoclax Treatment
- GSM9725387 TMD8 Cells,Wildtype Clone 5,Bexobrutidig-Venetoclax Treatment
- GSM9725388 TMD8 Cells,Wildtype Clone 5,Pomalidomide-Venetoclax Treatment
+ 60 more — browse all 100 samples with per-sample file links →
- GSE292026 2p Gain-Driven REL Overexpression Confers Resistance to BTK Inhibitors in Chronic Lymphocytic Leukemia 5 samples same disease briefing · shares btk, inhibitors
- GSE283045 PD-1 expression identifies activated and proliferating chronic lymphocytic leukemia cells and is a potential biomarker that informs response and resistance to BTK inhibitor therapy 35 samples same disease briefing · shares btk
- GSE319429 Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader 32 samples same disease briefing · shares btk
- GSE245432 Treatment of chronic lymphocytic leukemia cells with signaling inhibitors 14 samples same disease briefing · shares inhibitors
- GSE246521 Chronic Lymphocytic Leukemia in African Ancestry Population is Characterized by Increased Genomic Instability 350 samples same disease briefing
- GSE136634 Clinical and biological implications of target occupancy in chronic lymphocytic leukemia treated with acalabrutinib 124 samples same disease briefing
- GSE313098 Time-series RNA-seq analysis reveals dynamic transcriptional responses and crosstalk in chronic lymphocytic leukaemia (CLL) autologous and monoculture in vitro models 60 samples same disease briefing
- GSE305855 Casein kinase 1δ/ε inhibition suppresses CLL through cell-intrinsic and microenvironmental mechanisms [RNA-Seq] 42 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.